WO2009079587A3 - Biomarkers for sensitivity to anti-igf1r therapy - Google Patents
Biomarkers for sensitivity to anti-igf1r therapy Download PDFInfo
- Publication number
- WO2009079587A3 WO2009079587A3 PCT/US2008/087240 US2008087240W WO2009079587A3 WO 2009079587 A3 WO2009079587 A3 WO 2009079587A3 US 2008087240 W US2008087240 W US 2008087240W WO 2009079587 A3 WO2009079587 A3 WO 2009079587A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- biomarkers
- sensitivity
- methods
- igf1r
- therapy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q99/00—Subject matter not provided for in other groups of this subclass
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Theoretical Computer Science (AREA)
- General Physics & Mathematics (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- General Business, Economics & Management (AREA)
- Business, Economics & Management (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/808,270 US20110091524A1 (en) | 2007-12-18 | 2008-12-17 | Biomarkers for sensitivity to anti-igf1r therapy |
EP08861138A EP2247757A2 (en) | 2007-12-18 | 2008-12-17 | Biomarkers for sensitivity to anti-igf1r therapy |
CA2709827A CA2709827A1 (en) | 2007-12-18 | 2008-12-17 | Biomarkers for sensitivity to anti-igf1r therapy |
MX2010006854A MX2010006854A (en) | 2007-12-18 | 2008-12-17 | Biomarkers for sensitivity to anti-igf1r therapy. |
JP2010539750A JP2011505873A (en) | 2007-12-18 | 2008-12-17 | Biomarkers of sensitivity to anti-IGF1R therapy |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1455607P | 2007-12-18 | 2007-12-18 | |
US61/014,556 | 2007-12-18 | ||
US1593807P | 2007-12-21 | 2007-12-21 | |
US61/015,938 | 2007-12-21 | ||
US2290908P | 2008-01-23 | 2008-01-23 | |
US61/022,909 | 2008-01-23 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2009079587A2 WO2009079587A2 (en) | 2009-06-25 |
WO2009079587A3 true WO2009079587A3 (en) | 2009-11-12 |
Family
ID=40796133
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2008/087240 WO2009079587A2 (en) | 2007-12-18 | 2008-12-17 | Biomarkers for sensitivity to anti-igf1r therapy |
Country Status (6)
Country | Link |
---|---|
US (1) | US20110091524A1 (en) |
EP (1) | EP2247757A2 (en) |
JP (2) | JP2011505873A (en) |
CA (1) | CA2709827A1 (en) |
MX (1) | MX2010006854A (en) |
WO (1) | WO2009079587A2 (en) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102886045A (en) | 2005-02-03 | 2013-01-23 | 综合医院公司 | Method for treating gefitinib resistant cancer |
EP1942937A1 (en) | 2005-11-04 | 2008-07-16 | Wyeth | Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272 |
PE20090368A1 (en) | 2007-06-19 | 2009-04-28 | Boehringer Ingelheim Int | ANTI-IGF ANTIBODIES |
US8022216B2 (en) | 2007-10-17 | 2011-09-20 | Wyeth Llc | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
PL2310011T3 (en) | 2008-06-17 | 2013-12-31 | Wyeth Llc | Antineoplastic combinations containing hki-272 and vinorelbine |
SG10202102855RA (en) | 2008-08-04 | 2021-05-28 | Wyeth Llc | Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine |
BRPI0923359B8 (en) | 2008-12-12 | 2021-05-25 | Boehringer Ingelheim Int | anti-igf antibody molecule, method for producing the same, DNA molecule, expression vector, and pharmaceutical composition and in vitro method for inhibiting the binding of igf-1 and igf-2 to the igf-1 receptor and to the insulin receptor go-to |
MX356593B (en) | 2009-04-06 | 2018-06-05 | Wyeth Llc | Treatment regimen utilizing neratinib for breast cancer. |
CN102655864A (en) * | 2009-11-18 | 2012-09-05 | 赫尔辛医疗股份公司 | Compositions and methods for treating centrally mediated nausea and vomiting |
US9110082B2 (en) | 2009-11-30 | 2015-08-18 | Merck Sharp & Dohme Corp. | Methods for the identification and treatment of patients sensitive to anti IGF-1R inhibition therapy |
JP2014510265A (en) | 2011-02-02 | 2014-04-24 | アムジェン インコーポレイテッド | Methods and compositions for inhibition of IGF-IR |
US20120214830A1 (en) | 2011-02-22 | 2012-08-23 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma |
WO2012175481A1 (en) * | 2011-06-20 | 2012-12-27 | Institut Curie | Compositions and methods for treating leukemia |
US20150258170A1 (en) * | 2012-10-10 | 2015-09-17 | The Trustees Of Columbia University In The City Of New York | Diagnosis and Treatment of SMA and SMN Deficiency |
US10106855B2 (en) | 2012-11-09 | 2018-10-23 | The Johns Hopkins University | Genetic assay to determine prognosis in Polycythemia Vera patients |
US20140255413A1 (en) | 2013-03-07 | 2014-09-11 | Boehringer Ingelheim International Gmbh | Combination therapy for neoplasia treatment |
SG11201601424PA (en) | 2013-08-28 | 2016-03-30 | Stemcentrx Inc | Site-specific antibody conjugation methods and compositions |
JP2017514143A (en) | 2014-02-21 | 2017-06-01 | アッヴィ・ステムセントルクス・エル・エル・シー | Anti-DLL3 antibodies and drug conjugates for use in melanoma |
EP3550306B1 (en) * | 2014-08-26 | 2021-03-03 | Keio University | Anti-cancer agent sensitivity-determining marker |
US20170372347A1 (en) * | 2016-06-22 | 2017-12-28 | International Business Machines Corporation | Sequence-based marketing attribution model for customer journeys |
EP3665307B1 (en) * | 2017-08-10 | 2022-09-28 | The Institute of Cancer Research: Royal Cancer Hospital | Materials and methods for stratifying and treating cancers |
CN107714719A (en) * | 2017-11-08 | 2018-02-23 | 上海市第妇婴保健院 | Application of the rapamycin in the medicine for preparing treatment IL-27 low expression carcinoma of endometrium |
CN111394462A (en) * | 2020-04-13 | 2020-07-10 | 浙江大学 | Liver cancer sorafenib drug-resistant circRNA marker and application thereof |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004087756A2 (en) * | 2003-04-02 | 2004-10-14 | F. Hoffmann-La Roche Ag | Antibodies against insulin-like growth factor i receptor and uses thereof |
WO2006060419A2 (en) * | 2004-12-03 | 2006-06-08 | Schering Corporation | Biomarkers for pre-selection of patients for anti-igf1r therapy |
US20070065858A1 (en) * | 2005-09-20 | 2007-03-22 | Haley John D | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
US20070148145A1 (en) * | 2005-12-16 | 2007-06-28 | The Board Of Trustees Of The Leland Stanford Junior University | Protein modulators of resistance to alkylating agents |
WO2008076278A2 (en) * | 2006-12-13 | 2008-06-26 | Schering Corporation | Methods of cancer treatment with igf1r inhibitors |
WO2008144345A2 (en) * | 2007-05-17 | 2008-11-27 | Bristol-Myers Squibb Company | Biomarkers and methods for determining sensitivity to insulin growth factor-1 receptor modulators |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5856094A (en) * | 1995-05-12 | 1999-01-05 | The Johns Hopkins University School Of Medicine | Method of detection of neoplastic cells |
US5989885A (en) * | 1997-01-10 | 1999-11-23 | Myriad Genetics, Inc. | Specific mutations of map kinase 4 (MKK4) in human tumor cell lines identify it as a tumor suppressor in various types of cancer |
US7553485B2 (en) * | 2002-01-18 | 2009-06-30 | Pierre Fabre Medicament | Anti-IGF-IR and/or anti-insulin/IGF-I hybrid receptors antibodies and uses thereof |
US7241444B2 (en) * | 2002-01-18 | 2007-07-10 | Pierre Fabre Medicament | Anti-IGF-IR antibodies and uses thereof |
US20080063639A1 (en) * | 2002-01-18 | 2008-03-13 | Pierre Fabre Medicament | Method for the treatment of psoriasis comprising novel anti-IGF-IR antibodies |
US20080193445A1 (en) * | 2002-01-18 | 2008-08-14 | Liliane Goetsch | Novel anti-IGF-IR antibodies and uses thereof |
KR101086533B1 (en) * | 2002-05-24 | 2011-11-23 | 쉐링 코포레이션 | Neutralizing human anti-IGFR antibody, a method for producing it and a composition comprising it |
WO2005056764A2 (en) * | 2003-12-05 | 2005-06-23 | Compound Therapeutics, Inc. | Inhibitors of type 2 vascular endothelial growth factor receptors |
AU2006236637B2 (en) * | 2005-04-15 | 2012-09-06 | Merck Sharp & Dohme Corp. | Methods and compositions for treating or preventing cancer |
WO2008005469A2 (en) * | 2006-06-30 | 2008-01-10 | Schering Corporation | Igfbp2 biomarker |
-
2008
- 2008-12-17 JP JP2010539750A patent/JP2011505873A/en active Pending
- 2008-12-17 WO PCT/US2008/087240 patent/WO2009079587A2/en active Application Filing
- 2008-12-17 US US12/808,270 patent/US20110091524A1/en not_active Abandoned
- 2008-12-17 CA CA2709827A patent/CA2709827A1/en not_active Abandoned
- 2008-12-17 MX MX2010006854A patent/MX2010006854A/en unknown
- 2008-12-17 EP EP08861138A patent/EP2247757A2/en not_active Withdrawn
-
2013
- 2013-01-28 JP JP2013012872A patent/JP2013078341A/en active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004087756A2 (en) * | 2003-04-02 | 2004-10-14 | F. Hoffmann-La Roche Ag | Antibodies against insulin-like growth factor i receptor and uses thereof |
WO2006060419A2 (en) * | 2004-12-03 | 2006-06-08 | Schering Corporation | Biomarkers for pre-selection of patients for anti-igf1r therapy |
US20060140960A1 (en) * | 2004-12-03 | 2006-06-29 | Schering Corporation | Biomarkers for pre-selection of patients for anti-IGF1R therapy |
US20070065858A1 (en) * | 2005-09-20 | 2007-03-22 | Haley John D | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
US20070148145A1 (en) * | 2005-12-16 | 2007-06-28 | The Board Of Trustees Of The Leland Stanford Junior University | Protein modulators of resistance to alkylating agents |
WO2008076278A2 (en) * | 2006-12-13 | 2008-06-26 | Schering Corporation | Methods of cancer treatment with igf1r inhibitors |
WO2008144345A2 (en) * | 2007-05-17 | 2008-11-27 | Bristol-Myers Squibb Company | Biomarkers and methods for determining sensitivity to insulin growth factor-1 receptor modulators |
Non-Patent Citations (5)
Title |
---|
CHRISTOPHE DECHAMPS ET AL: "The Tre2 Oncoprotein, Implicated in Ewing's Sarcoma, Interacts with Two Components of the Cytoskeleton", BIOTECHNOLOGY LETTERS, KLUWER ACADEMIC PUBLISHERS, DO, vol. 28, no. 4, 1 February 2006 (2006-02-01), pages 223 - 231, XP019231204, ISSN: 1573-6776 * |
LI S-L ET AL: "Single-chain Antibodies Against Human Insulin-like Growth Factor I Receptor: Expression, Purification and Effect on Tumor Growth", CANCER IMMUNOLOGY AND IMMUNOTHERAPY, SPRINGER-VERLAG, BERLIN, DE, vol. 49, no. 4/05, 1 July 2000 (2000-07-01), pages 243 - 252, XP001113064, ISSN: 0340-7004 * |
MITSIADES CONSTANTINE S ET AL: "Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors", CANCER CELL, CELL PRESS, US, vol. 5, no. 3, 1 March 2004 (2004-03-01), pages 221 - 230, XP009100737, ISSN: 1535-6108 * |
OZBAS-GERCEKER F ET AL: "Serial analysis of gene expression in the hippocampus of patients with mesial temporal lobe epilepsy", NEUROSCIENCE, NEW YORK, NY, US, vol. 138, no. 2, 1 January 2006 (2006-01-01), pages 457 - 474, XP024986562, ISSN: 0306-4522, [retrieved on 20060101] * |
RIEDEMANN J ET AL: "IGF1R signalling and its inhibition", ENDOCRINE-RELATED CANCER, JOURNAL OF ENDOCRINOLOGY LTD., BRISTOL, GB, vol. 13, no. SUPPL. 1, 1 December 2006 (2006-12-01), pages S33 - S43, XP002481460, ISSN: 1351-0088 * |
Also Published As
Publication number | Publication date |
---|---|
WO2009079587A2 (en) | 2009-06-25 |
CA2709827A1 (en) | 2009-06-25 |
US20110091524A1 (en) | 2011-04-21 |
JP2013078341A (en) | 2013-05-02 |
MX2010006854A (en) | 2010-09-09 |
JP2011505873A (en) | 2011-03-03 |
EP2247757A2 (en) | 2010-11-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2009079587A3 (en) | Biomarkers for sensitivity to anti-igf1r therapy | |
PH12017500930A1 (en) | Hsp90 inhibitor combinations | |
WO2010056337A3 (en) | Methods and systems of using exosomes for determining phenotypes | |
TW200742570A (en) | Physiological function monitoring system | |
WO2008073899A3 (en) | Prrg4-associated compositions and methods of use thereof in methods of tumor diagnosis | |
WO2011046964A3 (en) | Inhibitors of bruton's tyrosine kinase | |
WO2009085234A3 (en) | Use of micro-rna as a biomarker of immunomodulatory drug activity | |
WO2007047955A3 (en) | Methods for prediction and prognosis of cancer, and monitoring cancer therapy | |
WO2011151252A3 (en) | Means and methods for diagnosing pancreatic cancer in a subject | |
WO2009126934A3 (en) | Detection and tratment of pancreatic, ovarian and other cancers | |
WO2007067968A3 (en) | Effects of inhibitors of fgfr3 on gene transcription | |
MX2010003424A (en) | Measuring mechanical properties. | |
WO2012149493A3 (en) | Hsp90 combination therapy | |
WO2009012140A3 (en) | Drug selection for lung cancer therapy using antibody-based arrays | |
WO2008097908A3 (en) | Methods of diagnosing and prognosing lung cancer | |
WO2007123722A3 (en) | Methods for prediction and prognosis of cancer, and monitoring cancer therapy | |
WO2008131361A3 (en) | Biosensors for measuring analytes in the interstitial fluid | |
WO2012082494A3 (en) | The use of anti-cxcl13 and anti-cxcr5 antibodies for the treatment or detection of cancer | |
WO2006057997A3 (en) | Plasmin-inhibitory therapies | |
WO2008070472A3 (en) | Use of plasma hsp90 related to malignancy | |
WO2010009171A3 (en) | Src activation for determining cancer prognosis and as a target for cancer therapy | |
WO2005080593A3 (en) | P53 wild-type as biomarker for the treatment with mtor inhibitors in combination with a cytotoxic agent | |
WO2011074802A3 (en) | Kit for diagnosing prostate cancer and diagnosis method | |
WO2009140505A3 (en) | Methods and systems for detecting concealed objects | |
WO2010053816A3 (en) | Biomarkers for diagnosis of breast cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08861138 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010539750 Country of ref document: JP Ref document number: 2709827 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2010/006854 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008861138 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12808270 Country of ref document: US |